Indian Journal of Critical Care Medicine

Register      Login



Volume / Issue

Online First

Related articles

VOLUME 26 , ISSUE 8 ( August, 2022 ) > List of Articles


Risk Factors and Clinical Outcomes of Stenotrophomonas maltophilia Infections: Scenario in a Tertiary Care Center from South India

Krithika Varshini, Vithiya Ganesan, Raja Sundaramurthy, T Rajendran

Keywords : Infection control, Nosocomial infection, Stenotrophomonas maltophilia

Citation Information : Varshini K, Ganesan V, Sundaramurthy R, Rajendran T. Risk Factors and Clinical Outcomes of Stenotrophomonas maltophilia Infections: Scenario in a Tertiary Care Center from South India. Indian J Crit Care Med 2022; 26 (8):935-937.

DOI: 10.5005/jp-journals-10071-24288

License: CC BY-NC 4.0

Published Online: 30-07-2022

Copyright Statement:  Copyright © 2022; The Author(s).


Stenotrophomonas maltophilia, a gram-negative non-fermenter has evolved from a colonizer to a significant pathogen over the last decade. It resides in various ecological niches both inside and outside the hospital settings. Infections due to S. maltophilia can be life-threatening, especially in immunocompromised patients. S. maltophilia is intrinsically resistant to most of the antibiotics, which limits treatment options. There are several risk factors involved. The present study was done to assess the risk factors and clinical outcomes associated with S. maltophilia blood stream infections and non-blood stream infections.

PDF Share
  1. Baidya A, Kodan P, Fazal F, Tsering S, Menon PR, Jorwal P, et al. Stenotrophomonas maltophilia: more than just a colonizer! Indian J Crit Care Med 2019;23(9):434–436. DOI: 10.5005/jp-journals-10071- 23241.
  2. Adegoke AA, Stenström TA, Okoh AI. Stenotrophomonas maltophilia as an emerging ubiquitous pathogen: looking beyond contemporary antibiotic therapy. Front Microbiol 2017;8:2276. DOI: 10.3389/fmicb.2017.02276.
  3. Singhal L, Kaur P, Gautam V. Stenotrophomonas maltophilia: from trivial to grievous. Indian J Med Microbiol 2017;35(4):469–479. DOI: 10.4103/ijmm.IJMM_16_430.
  4. Sumida K, Chong Y, Miyake N, Akahoshi T, Yasuda M, Shimono N, et al. Risk factors associated with Stenotrophomonas maltophilia bacteremia: a matched case-control study. PLoS One 2015;10(7): e0133731. DOI: 10.1371/journal.pone.0133731.
  5. Juhász E, Krizsán G, Lengyel G, Grósz G, Pongrácz J, Kristóf K. Infection and colonization by Stenotrophomonas maltophilia: antimicrobial susceptibility and clinical background of strains isolated at a tertiary care centre in Hungary. Ann Clin Microbiol Antimicrob 2014;13:333. DOI: 10.1186/s12941-014-0058-9.
  6. Abbott IJ, Slavin MA, Turnidge JD, Thursky KA, Worth LJ. Stenotrophomonas maltophilia: emerging disease patterns and challenges for treatment. Expert Rev Anti Infect Ther 2011;9(4): 471–488. DOI: 10.1586/eri.11.24.
  7. Gupta P, Kale P, Khillan V. Resurgence of global opportunistic multidrug-resistant Stenotrophomonas maltophilia. Indian J Crit Care Med 2018;22(7):503–508. DOI: 10.4103/ijccm.IJCCM_106_18.
  8. Hashimoto T, Komiya K, Fujita N, Usagawa Y, Yamasue M, Umeki K, et al. Risk factors for 30-day mortality among patients with Stenotrophomonas maltophilia bacteremia. Infect Dis 2020;52(6): 440–442. DOI: 10.1080/23744235.2020.1734653.
  9. Kannangara D, Pandya D. Stenotrophomonas maltophilia: attributable mortality may be overestimated. Int J Infect Dis 2020;101(1):146–147. DOI: 10.1016/j.ijid.2020.09.396.
  10. Gautam V, Kumar S, Kaur P, Deepak T, Singhal L, Tewari R, et al. Antimicrobial susceptibility pattern of Burkholderia cepacia complex & Stenotrophomonas maltophilia over six years (2007-2012). Indian J Med Res 2015;142(4):492–494. DOI: 10.4103/0971-5916.169225.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.